Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-06
2007-02-06
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252180, C544S360000, C540S484000
Reexamination Certificate
active
09117436
ABSTRACT:
Compounds of formula (I), wherein G1is CH or N; G2is CH or N; R1is a variety of optional substituents; L1is (1-4C)alkylene; T1is CH or N; R2and R3are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X1and X2represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described.
REFERENCES:
patent: 4167567 (1979-09-01), McCall
patent: 5332822 (1994-07-01), Misra
patent: 5371091 (1994-12-01), Misra et al.
patent: 5411971 (1995-05-01), Emonds-Alt et al.
patent: 5606065 (1997-02-01), Emonds-Alt et al.
patent: 5856326 (1999-01-01), Anthony et al.
patent: 10177/92 (1992-07-01), None
patent: 42 43 858 (1994-06-01), None
patent: 43 06 506 (1994-09-01), None
patent: 0 233 051 (1987-08-01), None
patent: 0 244 115 (1987-11-01), None
patent: 0 308 337 (1989-03-01), None
patent: 0 359 389 (1990-03-01), None
patent: 0 409 413 (1991-01-01), None
patent: 0 495 750 (1992-07-01), None
patent: 0 515 240 (1992-11-01), None
patent: 0 519 449 (1992-12-01), None
patent: 0 576 941 (1994-01-01), None
patent: 0691959 (1996-01-01), None
patent: 1 449 100 (1976-09-01), None
patent: WO 92/18478 (1992-10-01), None
patent: WO 93/06085 (1993-04-01), None
patent: WO 94/20467 (1994-09-01), None
patent: WO 94/20468 (1994-09-01), None
patent: WO 96/10022 (1996-04-01), None
patent: WO 96/26196 (1996-08-01), None
patent: WO 96/30343 (1996-10-01), None
patent: WO 97/096802 (1997-02-01), None
patent: WO 97/28128 (1997-08-01), None
patent: WO 97/28129 (1997-08-01), None
patent: WO 97/30971 (1997-08-01), None
patent: WO 98/06705 (1998-02-01), None
Thomae et al., Arzneim. -Forsch., Synthesis and N-benzylaminocarboxylic acids and their deriviatives, vol. 23(2a), pp. 290-295, 1973.
Budavari: Merck Index, Vol 11 Ed., 1989, See Monograph Nos. 804 and 2807.
Cattel et al: “Drug design based on biosynthetic studies: synthesis, biological activity, and kinetics of new inhibitors of 2,3-oxidosualene cyclase and squalene epoxidase.”, Steroids., vol 53, no 3-5, 1989, pp. 363-391, XP000611661.
Sartori et al., “Synthesis and analgesic activities of urea derivatives of α-amino-N-pyridyl benzene propanamide”, Eur J. Med Chem (1994), 431-439.
Tabacik et al: “Squalene expoxidase, oxido-squalene cyclase and cholesterol biosynthesis in normal and tumoral mucosa of the human gastrointestinal tract. Evidence of post-HMGCoA regulation.”, Biochim. Biophys. Acta, vol 666, No. 3, 1982, pp. 433-441, XP000610864.
Wallis, “Inhibitors of Coagulation Factor Xa: From Macromolecular Beginnings to Small Molecules”, Current Opinion in Therapeutic Patents, Aug., 1993, pp. 1173-1179.
R.B. Wallis, “Inhibitors of Coagulation Factor Xa: From Macromolecular Beginnings to Small Molecules”, Current Opinion in Therapeutic Patents, London, pp. 1173-1179, (1993).
S. Budavari et al., “The Merck Index, 12 Edition”, Merck Research Laboratories, Whitehouse Station, N.J., pp. 131, 132 and 476, (1996).
C. Kettner et al., “The Selective Inhibition of Thrombin by Peptides of Boroarginine”, The Journal of Biological Chemistry, vol. 265, No. 30, pp. 18289-18297, (1990).
Gerard M.T. Vogel et al., “Comparison of Two Experimental Thrombosis Models in Rats Effects of Four Glycosaminogylcans”, Thrombosis Research, vol. 54, No. 5, pp. 399-410, (1989).
J.R. Smith et al., “Fibrin, Red Cell and Platelet Interactions in an Experimental Model of Thrombosis”, Br. J. Pharmac., vol. 77, pp. 29-38, (1982).
P.E. Cross et al., “Preparation of N-[(heterocyclylmethoxy) phenyl] sulfamides and analogs as antiarrhythmics”, Chemical Abstracts, Abstract No. 231211, vol. 113, (1989).
A. Vigroux et al., “Cyclization-Activated Prodrugs: N-(Substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates Based on Ring-Opened Derivatives of Active Benzoxazolones and Oxazolidinones as Mutual Prodrugs of Acetaminophen”, J. Med. Chem., Vol 38, pp. 3983-3994, (1995).
P.A. Chambers et al., “Preparation of arylpyridine compounds for treating leukotriene-related diseases”, Chemical Abstracts, Abstract No. 139113, vol. 119, (1993).
H. Harry Szmant et al., “Concerning the Variable Character of the Sulfone Group”, J. Amer. Chem. Soc., vol. 78, pp. 3400-3403, (1956).
Preston John
Smithers Michael James
Stocker Andrew
Morgan & Lewis & Bockius, LLP
Robinson Binta
Rotman Alan L.
Zeneca Limited
LandOfFree
Aminoheterocyclic derivatives as antithrombotic or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoheterocyclic derivatives as antithrombotic or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoheterocyclic derivatives as antithrombotic or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3848514